Corbus shareholders approve reverse stock split at ratio up to 1:40

Corbus Pharmaceuticals Holdings, Inc.

Shareholders approved amendment to authorize reverse split from 1:4 to 1:40, board to set exact ratio.
Adjournment proposal also approved; both items passed at special meeting on Dec 20, 2022.
Record date for voting was Nov 7, 2022, with 125,280,881 common shares outstanding.
Final vote on reverse split: 25.79 trillion for, 5.06 trillion against, 0.47 trillion abstentions.
Reverse split intended to meet Nasdaq listing requirements and raise per-share price.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Corbus Pharmaceuticals Holdings, Inc. shareholders approved Adoption and approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of common stock at a ratio from 1:4 to 1:40 at the 2022-12-20 meeting.

Proposal: reverse split
Outcome: passed
Meeting: 2022-12-20

Exact text from the filing

1. The Reverse Stock Split Proposal. The votes were cast for this matter as follows: Votes For Votes Against Abstentions 25,794,110,289,993 5,064,240,621,803 474,524,757,330

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Corbus Pharmaceuticals Holdings, Inc. shareholders approved Approval of the adjournment of the Special Meeting to the extent there are insufficient votes to approve the Reverse Stock Split Proposal at the 2022-12-20 meeting.

Proposal: reverse split
Outcome: passed
Meeting: 2022-12-20

Exact text from the filing

2. The Adjournment Proposal. The votes were cast for this matter as follows: Votes For Votes Against Abstentions 51,281,428 10,784,629 603,069

View on SEC.gov

1180 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Corbus Pharmaceuticals Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-026875

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.